Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Penny For Your Thoughts? HHS Secretary Azar’s Blunt Words For 340B Providers

Executive Summary

Azar didn’t bring much comforting news to attendees at the annual 340B Coalition conference, with a strong defense of cuts in reimbursement for providers who use the drug discount program. But he did suggest that the 'penny pricing' policy will be finalized soon.

You may also be interested in...



340B Payment Cut Overturned By US Federal Court; What Comes Next?

Siding with coalition of hospitals, judge ruled that HHS lacked authority to cut Medicare reimbursement for drugs purchased at 340B prices. That should change the dynamics of the 340B reform debate heading into 2019 – but don’t expect the Trump Administration to back down on its push to rein in what it sees as abuses of the discount.

340B Drug Pricing, Penalties Need To Be Implemented, Congressional Leaders Say

Leaders of key health care committees urge HRSA to move ahead quickly with regulations, which might mean implementing a 2017 final rule or issuing a new proposed rule.

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

After a conversation with President Trump, CEO Ian Read agreed to cancel price increases on 40 drugs that took effect July 1, to give the administration time to work on its blueprint for improving the health care system.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel